Nasdaq · CIK 0000914475
NBIX NEUROCRINE BIOSCIENCES INC
Insider trading from SEC Form 4. Last filing 27 d ago. Close $142.44 on Oct 9, 2026, +16% from the 52-week low and -23% from the high.
Last 90 days
Net insider value
-$826k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$826k by 3 insiders
Insiders on file
19
with a Form 4 at this company
Price and insider trades, last year
NBIXOct 9, 2026 · close 142.44
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NEUROCRINE BIOSCIENCES INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Matt Abernethy Chief Financial Officer sell | $363k 2,311 shares | -5% | - | |
| 21Weak | David W. Boyer Chief Corp. Affairs Officer sell | $130k 826 shares | -9% | - | |
| 10Weak | Eric Benevich Chief Commercial Officer sell | $333k 2,154 shares | -3% | - | |
| 0Weak | Ingrid Delaet Chief Regulatory Officer sell | $62k 457 shares | -9% | +54% from low-12% from high | |
| 20Weak | Kevin Charles Gorman director sell | $1.2M 9,613 shares | -2% | +40% from low-20% from high | |
| 15Weak | William H Rastetter director sell | $3.3M 30,000 shares | -44% | +25% from low-28% from high | |
| 16Weak | Matt Abernethy Chief Financial Officer sell | $299k 2,558 shares | -7% | - | |
| 8Weak | Eric Benevich Chief Commercial Officer sell | $251k 2,154 shares | -5% | - | |
| 17Weak | David W. Boyer Chief Corp. Affairs Officer sell | $208k 1,785 shares | -47% | - | |
| 7Weak | Julie Cooke Chief Human Resources Officer sell | $181k 1,551 shares | -8% | - | |
| 16Weak | Ingrid Delaet Chief Regulatory Officer sell | $172k 1,471 shares | -31% | - | |
| 16Weak | Kevin Charles Gorman director sell | $682k 5,844 shares | -1% | - | |
| 19Weak | Kyle Gano Chief Executive Officer sell | $299k 2,558 shares | -2% | - | |
| 12Weak | Matt Abernethy Chief Financial Officer sell | $116k 980 shares | -3% | - | |
| 5Weak | Eric Benevich Chief Commercial Officer sell | $116k 980 shares | -2% | - | |
| 14Weak | David W. Boyer Chief Corp. Affairs Officer sell | $83k 700 shares | -26% | - | |
| 4Weak | Julie Cooke Chief Human Resources Officer sell | $83k 700 shares | -4% | - | |
| 8Weak | Kevin Charles Gorman director sell | $269k 2,274 shares | -0% | - | |
| 15Weak | Kyle Gano Chief Executive Officer sell | $116k 980 shares | -1% | - | |
| 14Weak | Matt Abernethy Chief Financial Officer sell | $196k 1,283 shares | -4% | - | |
| 7Weak | Eric Benevich Chief Commercial Officer sell | $185k 1,207 shares | -3% | - | |
| 16Weak | David W. Boyer Chief Corp. Affairs Officer sell | $169k 1,104 shares | -45% | - | |
| 8Weak | Julie Cooke Chief Human Resources Officer sell | $266k 1,740 shares | -9% | - | |
| 16Weak | Ingrid Delaet Chief Regulatory Officer sell | $158k 1,045 shares | -32% | - | |
| 11Weak | Kevin Charles Gorman director sell | $414k 2,707 shares | -1% | - | |
| 18Weak | Kyle Gano Chief Executive Officer sell | $236k 1,541 shares | -1% | - | |
| 25Weak | Kevin Charles Gorman director sell | $22M 146,105 shares | -22% | - | |
| 33Weak | Kyle Gano Chief Executive Officer sell | $9.2M 65,000 shares | -46% | - | |
| 0Weak | Ingrid Delaet Chief Regulatory Officer sell | $38k 272 shares | -10% | - | |
| 1Weak | Ingrid Delaet Chief Regulatory Officer sell | $147k 1,091 shares | -30% | - | |
| 0Weak | Jude Onyia Chief Scientific Officer sell | $294k 2,331 shares | -13% | - |
Congressional trades
2 trades in NBIX disclosed by members of Congress under the STOCK Act. All congressional trades.
- Lisa C. McClainHouse · R-MI · last Aug 13, 20251 bought
1 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Lisa C. McClain House · R-MI | Partial sale | NBIX Neurocrine Biosciences, Inc. - Common Stock | $1,001 to $15k | Jun 17, 2025 / Aug 13, 2025 57 days after the trade | Clerk |
Lisa C. McClain House · R-MI | Purchase | NBIX Neurocrine Biosciences, Inc. - Common Stock | $1,001 to $15k | Jun 11, 2025 / Aug 13, 2025 63 days after the trade | Clerk |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Kyle Gano Chief Executive Officer | AGrant or award Common Stock | +6,275 | $0.00 | $0 | 157,266 | 27 d ago |
| Sep 11, 2026 | David W. Boyer Chief Corp. Affairs Officer | AGrant or award Common Stock10b5-1 | +3,587 | $0.00 | $0 | 11,484 | 27 d ago |
| Sep 11, 2026 | Matt Abernethy Chief Financial Officer | AGrant or award Common Stock10b5-1 | +5,020 | $0.00 | $0 | 47,828 | 27 d ago |
| Sep 11, 2026 | Sanjay Chandru Keswani Chief Medical Officer | AGrant or award Common Stock | +3,914 | $0.00 | $0 | 5,393 | 27 d ago |
| Sep 11, 2026 | Eric Benevich Chief Commercial Officer | AGrant or award Common Stock | +6,275 | $0.00 | $0 | 70,683 | 27 d ago |
| Sep 11, 2026 | Ingrid Delaet Chief Regulatory Officer | AGrant or award Common Stock | +4,483 | $0.00 | $0 | 20,708 | 27 d ago |
| Sep 11, 2026 | Julie Cooke Chief Human Resources Officer | AGrant or award Common Stock | +3,587 | $0.00 | $0 | 25,961 | 27 d ago |
| Sep 11, 2026 | Jude Onyia Chief Scientific Officer | AGrant or award Common Stock | +3,587 | $0.00 | $0 | 24,583 | 27 d ago |
| Sep 11, 2026 | Darin Lippoldt Chief Legal Officer | AGrant or award Common Stock | +4,483 | $0.00 | $0 | 59,212 | 27 d ago |
| Sep 11, 2026 | Kevin Charles Gorman director | AGrant or award Common Stock | +14,343 | $0.00 | $0 | 525,636 | 27 d ago |
| Sep 11, 2026 | Matt Abernethy Chief Financial Officer | FTax withholding Common Stock10b5-1 | -2,709 | $156.22 | $423k | 45,119 | 27 d ago |
| Sep 11, 2026 | Sanjay Chandru Keswani Chief Medical Officer | FTax withholding Common Stock | -2,112 | $156.22 | $330k | 3,281 | 27 d ago |
| Sep 11, 2026 | Kyle Gano Chief Executive Officer | FTax withholding Common Stock | -3,386 | $156.22 | $529k | 153,880 | 27 d ago |
| Sep 11, 2026 | David W. Boyer Chief Corp. Affairs Officer | FTax withholding Common Stock10b5-1 | -1,936 | $156.22 | $302k | 9,548 | 27 d ago |
| Sep 11, 2026 | Darin Lippoldt Chief Legal Officer | FTax withholding Common Stock | -2,419 | $156.22 | $378k | 56,793 | 27 d ago |
| Sep 11, 2026 | Julie Cooke Chief Human Resources Officer | FTax withholding Common Stock | -1,936 | $156.22 | $302k | 24,025 | 27 d ago |
| Sep 11, 2026 | Jude Onyia Chief Scientific Officer | FTax withholding Common Stock | -1,936 | $156.22 | $302k | 22,647 | 27 d ago |
| Sep 11, 2026 | Kevin Charles Gorman director | FTax withholding Common Stock | -7,839 | $156.22 | $1.2M | 517,797 | 27 d ago |
| Sep 11, 2026 | Ingrid Delaet Chief Regulatory Officer | FTax withholding Common Stock | -2,419 | $156.22 | $378k | 18,289 | 27 d ago |
| Sep 11, 2026 | Eric Benevich Chief Commercial Officer | FTax withholding Common Stock | -3,386 | $156.22 | $529k | 67,297 | 27 d ago |
| Sep 11, 2026 | Kyle Gano Chief Executive Officer | AGrant or award Common Stock | +1,842 | $0.00 | $0 | 155,722 | 27 d ago |
| Sep 14, 2026 | David W. Boyer Chief Corp. Affairs Officer | SOpen-market sale Common Stock10b5-1 | -826 | $157.45 | $130k | 8,722 | 27 d ago |
| Sep 14, 2026 | Matt Abernethy Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -2,311 | $157.20 | $363k | 42,808 | 27 d ago |
| Sep 11, 2026 | Kyle Gano Chief Executive Officer | FTax withholding Common Stock | -994 | $156.22 | $155k | 154,728 | 27 d ago |
| Sep 9, 2026 | Eric Benevich Chief Commercial Officer | MOption exercise Common Stock10b5-1 | +3,194 | $43.24 | $138k | 66,562 | 32 d ago |
| Sep 9, 2026 | Eric Benevich Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -2,154 | $154.61 | $333k | 64,408 | 32 d ago |
| Sep 9, 2026 | Eric Benevich Chief Commercial Officer | MOption exercise Incentive Stock Optionderivative10b5-1 | -3,194 | $0.00 | $0 | 0 | 32 d ago |
| Sep 2, 2026 | Stephen A Sherwin director | GGift Common Stock | -1,000 | $0.00 | $0 | 14,860 | 39 d ago |
| Jul 10, 2025 | Ingrid Delaet Chief Regulatory Officer | MOption exercise Common Stock10b5-1 | +457 | $79.02 | $36k | 5,187 | Jul 11, 2025 |
| Jul 10, 2025 | Ingrid Delaet Chief Regulatory Officer | SOpen-market sale Common Stock10b5-1 | -457 | $135.00 | $62k | 4,730 | Jul 11, 2025 |
| Jul 10, 2025 | Ingrid Delaet Chief Regulatory Officer | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -457 | $0.00 | $0 | 2,261 | Jul 11, 2025 |
| Jun 2, 2025 | Sanjay Chandru Keswani Chief Medical Officer | AGrant or award Restricted Stock Unitderivative | +12,846 | $0.00 | $0 | 12,846 | Jun 4, 2025 |
| Jun 2, 2025 | Sanjay Chandru Keswani Chief Medical Officer | AGrant or award Stock Optionderivative | +70,101 | $0.00 | $0 | 70,101 | Jun 4, 2025 |
| May 27, 2025 | Kevin Charles Gorman director | SOpen-market sale Common Stock10b5-1 | -9,613 | $120.38 | $1.2M | 514,596 | May 29, 2025 |
| May 22, 2025 | Gary A Lyons director | MOption exercise Common Stock | +1,435 | $0.00 | $0 | 120,482 | May 22, 2025 |
| May 22, 2025 | George J Morrow director | MOption exercise Common Stock | +2,869 | $0.00 | $0 | 7,068 | May 22, 2025 |
| May 22, 2025 | Johanna Mercier director | MOption exercise Common Stock | +1,435 | $0.00 | $0 | 3,535 | May 22, 2025 |
| May 22, 2025 | Leslie Norwalk V director | MOption exercise Common Stock | +1,435 | $0.00 | $0 | 2,429 | May 22, 2025 |
| May 22, 2025 | Richard F Pops director | MOption exercise Common Stock | +2,869 | $0.00 | $0 | 34,480 | May 22, 2025 |
| May 22, 2025 | Stephen A Sherwin director | MOption exercise Common Stock | +2,869 | $0.00 | $0 | 13,542 | May 22, 2025 |
| May 22, 2025 | Shalini Sharp director | MOption exercise Common Stock | +1,435 | $0.00 | $0 | 2,429 | May 22, 2025 |
| May 22, 2025 | Christine A Poon director | MOption exercise Common Stock | +1,435 | $0.00 | $0 | 1,435 | May 22, 2025 |
| May 22, 2025 | William H Rastetter director | MOption exercise Common Stock | +2,869 | $0.00 | $0 | 40,360 | May 22, 2025 |
| May 21, 2025 | Kevin Charles Gorman director | AGrant or award Non-Qualified Stock Optionderivative | +6,610 | $0.00 | $0 | 6,610 | May 22, 2025 |
| May 21, 2025 | George J Morrow director | AGrant or award Restricted Stock Unitderivative | +3,318 | $0.00 | $0 | 3,318 | May 22, 2025 |
| May 21, 2025 | Christine A Poon director | AGrant or award Restricted Stock Unitderivative | +3,318 | $0.00 | $0 | 3,318 | May 22, 2025 |
| May 21, 2025 | William H Rastetter director | AGrant or award Restricted Stock Unitderivative | +3,318 | $0.00 | $0 | 3,318 | May 22, 2025 |
| May 21, 2025 | Gary A Lyons director | AGrant or award Restricted Stock Unitderivative | +1,659 | $0.00 | $0 | 1,659 | May 22, 2025 |
| May 21, 2025 | Johanna Mercier director | AGrant or award Restricted Stock Unitderivative | +3,318 | $0.00 | $0 | 3,318 | May 22, 2025 |
| May 21, 2025 | Leslie Norwalk V director | AGrant or award Restricted Stock Unitderivative | +1,659 | $0.00 | $0 | 1,659 | May 22, 2025 |
| May 21, 2025 | Richard F Pops director | AGrant or award Restricted Stock Unitderivative | +3,318 | $0.00 | $0 | 3,318 | May 22, 2025 |
| May 21, 2025 | Stephen A Sherwin director | AGrant or award Restricted Stock Unitderivative | +3,318 | $0.00 | $0 | 3,318 | May 22, 2025 |
| May 21, 2025 | Shalini Sharp director | AGrant or award Restricted Stock Unitderivative | +1,659 | $0.00 | $0 | 1,659 | May 22, 2025 |
| May 22, 2025 | Christine A Poon director | MOption exercise Restricted Stock Unitderivative | -1,435 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | George J Morrow director | MOption exercise Restricted Stock Unitderivative | -2,869 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | Johanna Mercier director | MOption exercise Restricted Stock Unitderivative | -1,435 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | Richard F Pops director | MOption exercise Restricted Stock Unitderivative | -2,869 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | Stephen A Sherwin director | MOption exercise Restricted Stock Unitderivative | -2,869 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | William H Rastetter director | MOption exercise Restricted Stock Unitderivative | -2,869 | $0.00 | $0 | 0 | May 22, 2025 |
| May 21, 2025 | Gary A Lyons director | AGrant or award Non-Qualified Stock Optionderivative | +3,305 | $0.00 | $0 | 3,305 | May 22, 2025 |
| May 21, 2025 | Leslie Norwalk V director | AGrant or award Non-Qualified Stock Optionderivative | +3,305 | $0.00 | $0 | 3,305 | May 22, 2025 |
| May 21, 2025 | Shalini Sharp director | AGrant or award Non-Qualified Stock Optionderivative | +3,305 | $0.00 | $0 | 3,305 | May 22, 2025 |
| May 22, 2025 | Gary A Lyons director | MOption exercise Restricted Stock Unitderivative | -1,435 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | Leslie Norwalk V director | MOption exercise Restricted Stock Unitderivative | -1,435 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | Shalini Sharp director | MOption exercise Restricted Stock Unitderivative | -1,435 | $0.00 | $0 | 0 | May 22, 2025 |
| May 16, 2025 | Julie Cooke Chief Human Resources Officer | MOption exercise Common Stock | +6,468 | $61.82 | $400k | 26,858 | May 20, 2025 |
| May 16, 2025 | Julie Cooke Chief Human Resources Officer | MOption exercise Incentive Stock Optionderivative | -6,468 | $0.00 | $0 | 0 | May 20, 2025 |
| May 5, 2025 | William H Rastetter director | MOption exercise Common Stock10b5-1 | +30,000 | $42.76 | $1.3M | 67,491 | May 7, 2025 |
| May 5, 2025 | William H Rastetter director | SOpen-market sale Common Stock10b5-1 | -30,000 | $110.20 | $3.3M | 37,491 | May 7, 2025 |
| May 5, 2025 | William H Rastetter director | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -30,000 | $0.00 | $0 | 0 | May 7, 2025 |
| Feb 13, 2025 | Matt Abernethy Chief Financial Officer | MOption exercise Common Stock10b5-1 | +2,566 | $0.00 | $0 | 36,127 | Feb 14, 2025 |
| Feb 13, 2025 | Eric Benevich Chief Commercial Officer | MOption exercise Common Stock10b5-1 | +2,083 | $0.00 | $0 | 44,882 | Feb 14, 2025 |
| Feb 13, 2025 | Kyle Gano Chief Executive Officer | MOption exercise Common Stock10b5-1 | +2,566 | $0.00 | $0 | 140,224 | Feb 14, 2025 |
| Feb 13, 2025 | Kevin Charles Gorman director | MOption exercise Common Stock10b5-1 | +5,376 | $0.00 | $0 | 524,450 | Feb 14, 2025 |
| Feb 13, 2025 | David W. Boyer Chief Corp. Affairs Officer | MOption exercise Common Stock10b5-1 | +1,811 | $0.00 | $0 | 3,809 | Feb 14, 2025 |
| Feb 13, 2025 | Julie Cooke Chief Human Resources Officer | MOption exercise Common Stock10b5-1 | +1,509 | $0.00 | $0 | 20,340 | Feb 14, 2025 |
| Feb 13, 2025 | Ingrid Delaet Chief Regulatory Officer | MOption exercise Common Stock10b5-1 | +1,358 | $0.00 | $0 | 4,800 | Feb 14, 2025 |
| Feb 13, 2025 | Matt Abernethy Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -1,352 | $116.85 | $158k | 34,775 | Feb 14, 2025 |
| Feb 13, 2025 | Eric Benevich Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -1,098 | $116.74 | $128k | 43,784 | Feb 14, 2025 |
| Feb 13, 2025 | Kyle Gano Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,352 | $116.84 | $158k | 138,872 | Feb 14, 2025 |
| Feb 13, 2025 | Kevin Charles Gorman director | SOpen-market sale Common Stock10b5-1 | -2,832 | $116.69 | $330k | 521,618 | Feb 14, 2025 |
| Feb 13, 2025 | David W. Boyer Chief Corp. Affairs Officer | SOpen-market sale Common Stock10b5-1 | -955 | $116.79 | $112k | 2,854 | Feb 14, 2025 |
| Feb 13, 2025 | Julie Cooke Chief Human Resources Officer | SOpen-market sale Common Stock10b5-1 | -796 | $116.77 | $93k | 19,544 | Feb 14, 2025 |
| Feb 13, 2025 | Ingrid Delaet Chief Regulatory Officer | SOpen-market sale Common Stock10b5-1 | -716 | $116.69 | $84k | 4,084 | Feb 14, 2025 |
| Feb 13, 2025 | Matt Abernethy Chief Financial Officer | MOption exercise Common Stock10b5-1 | +2,241 | $0.00 | $0 | 37,016 | Feb 14, 2025 |
| Feb 13, 2025 | Eric Benevich Chief Commercial Officer | MOption exercise Common Stock10b5-1 | +1,961 | $0.00 | $0 | 45,745 | Feb 14, 2025 |
| Feb 13, 2025 | David W. Boyer Chief Corp. Affairs Officer | MOption exercise Common Stock10b5-1 | +1,541 | $0.00 | $0 | 4,395 | Feb 14, 2025 |
| Feb 13, 2025 | Kevin Charles Gorman director | MOption exercise Common Stock10b5-1 | +5,603 | $0.00 | $0 | 527,221 | Feb 14, 2025 |
| Feb 13, 2025 | Julie Cooke Chief Human Resources Officer | MOption exercise Common Stock10b5-1 | +1,401 | $0.00 | $0 | 20,945 | Feb 14, 2025 |
| Feb 13, 2025 | Kyle Gano Chief Executive Officer | MOption exercise Common Stock10b5-1 | +2,241 | $0.00 | $0 | 141,113 | Feb 14, 2025 |
| Feb 13, 2025 | Ingrid Delaet Chief Regulatory Officer | MOption exercise Common Stock10b5-1 | +1,401 | $0.00 | $0 | 5,485 | Feb 14, 2025 |
| Feb 13, 2025 | Matt Abernethy Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -1,206 | $116.87 | $141k | 35,810 | Feb 14, 2025 |
| Feb 13, 2025 | Eric Benevich Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -1,056 | $116.71 | $123k | 44,689 | Feb 14, 2025 |
| Feb 13, 2025 | David W. Boyer Chief Corp. Affairs Officer | SOpen-market sale Common Stock10b5-1 | -830 | $116.69 | $97k | 3,565 | Feb 14, 2025 |
| Feb 13, 2025 | Julie Cooke Chief Human Resources Officer | SOpen-market sale Common Stock10b5-1 | -755 | $116.80 | $88k | 20,190 | Feb 14, 2025 |
| Feb 13, 2025 | Kyle Gano Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,206 | $116.86 | $141k | 139,907 | Feb 14, 2025 |
| Feb 13, 2025 | Kevin Charles Gorman director | SOpen-market sale Common Stock10b5-1 | -3,012 | $116.68 | $351k | 524,209 | Feb 14, 2025 |
| Feb 13, 2025 | Ingrid Delaet Chief Regulatory Officer | SOpen-market sale Common Stock10b5-1 | -755 | $116.72 | $88k | 4,730 | Feb 14, 2025 |
| Feb 12, 2025 | Matt Abernethy Chief Financial Officer | AGrant or award Stock Optionderivative10b5-1 | +45,538 | $0.00 | $0 | 45,538 | Feb 14, 2025 |
| Feb 13, 2025 | Kevin Charles Gorman director | MOption exercise Restricted Stock Unitderivative10b5-1 | -5,376 | $0.00 | $0 | 10,754 | Feb 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Matt AbernethyChief Financial Officer
- Eric BenevichChief Commercial Officer
- David W. BoyerChief Corp. Affairs Officer
- Julie CookeChief Human Resources Officer
- Ingrid DelaetChief Regulatory Officer
- Kevin Charles Gormandirector
- Kyle GanoChief Executive Officer
- Sanjay Chandru KeswaniChief Medical Officer
- Gary A Lyonsdirector
- Darin LippoldtChief Legal Officer
- George J Morrowdirector
- Johanna Mercierofficer, director
- Leslie Norwalk Vdirector
- Jude OnyiaChief Scientific Officer
- Christine A Poondirector
- Richard F Popsceo, officer, director
- William H Rastetterdirector
- Stephen A Sherwindirector
- Shalini Sharpdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.